Find drug development pipeline and deal Updates information

Lead Product(s): Promitil,Capecitabine,Bevacizumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

Study authors found that Promitil may be a useful agent in patients with metastatic colorectal cancer (CRC).

Lead Product(s): CM-24,Nivolumab

Therapeutic Area: Oncology

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Kitov Pharma

Deal Size: $13.5 million Upfront Cash: $13.5 million

Deal Type: Acquisition January 08, 2020

Details:

The acquisition strengthens Kitov’s oncology pipeline with the addition of novel checkpoint inhibitor, CM-24. Kitov intends to initiate a phase 1b/2a clinical trial of CM-24 + nivolumab.